Janssen gains immunotherapies, boosts prostate portfolio with Aduro deal
This article was originally published in Scrip
Johnson & Johnson's Janssen Biotech will pay up to $359m in upfront and milestone fees plus royalties to expand the companies' Zytiga-led prostate cancer portfolio with programs based on Aduro BioTech's immunotherapy technology.
You may also be interested in...
Immuno-oncology deals command relatively high values, but transaction volumes are increasing annually at a steady pace, not skyrocketing despite intense interest in the field as big pharma companies remain selective IO dealmakers based on the strength of early-stage data.
Private Company Edition: Venture capital invested in pharma and biotech in 2020 totaled $19.5m through Q3, just $400m below the full-year record total of $19.9bn in 2018. Also, Canaan and Catalio reveal new VC funds, while Talaris’s $115m series B leads recent financings.
Biopharma executives discussed their strategies for treating chronic diseases during the Cell and Gene Meeting on the Mesa, including R&D and regulatory considerations.